Table of Contents OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-40839 QT Imaging Holdings, Inc. (Exact name of registrant as specified in its charter) _________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly p ...

Exhibit 99.1 QT Imaging Announces Continuous Strong Revenue Growth and Enhanced Balance Sheet in the Second Quarter 2025 Announces New 'QTI Cloud Platform' as it Accelerates Its Transformation into a Precision Imaging AI Company NOVATO, CA – Aug 7, 2025 – QT Imaging Holdings, Inc. (OTCQB: QTIH) ("QT Imaging" or the "Company"), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results for the three and six months end ...

Financial Performance - The company has incurred a net loss of $11,136,000 for the three months ended March 31, 2025, and has an accumulated deficit of $43,076,527[140]. - Revenue for Q1 2025 increased by 105% to $2,798,415 compared to $1,362,163 in Q1 2024, primarily due to the sale of six QT Breast Scanners[158]. - Cost of revenue rose by 64% to $986,553 in Q1 2025 from $602,083 in Q1 2024, attributed to the increased sales of QT Breast Scanners[160]. - Gross profit for Q1 2025 was $1,811,862, a 138% increase from $760,080 in Q1 2024[158]. - Net loss for Q1 2025 was $11,136,000, a significant increase from a loss of $628,590 in Q1 2024, reflecting an increase in other expenses[158]. - The company had an accumulated deficit of $43,076,527 as of March 31, 2025, up from $31,940,527 at the end of 2024[169]. Funding and Capital Requirements - The company continues to incur losses and will need to raise additional capital to achieve profitability[140]. - The company expects to incur significant expenses for research and development, particularly for the QT Breast Scanner, and plans to raise capital through equity issuance and borrowings[189]. - The company anticipates that future funding requirements will depend on various factors, including growth rate and timing of expenditures[190]. - Future funding requirements may increase significantly based on factors such as debt obligations, manufacturing expansion, and regulatory clearances for the QT Breast Scanner[191]. - The company expects to finance cash needs through a combination of public or private equity offerings, debt financings, and strategic partnerships[193]. - If additional funds are not raised, the company may need to delay or reduce product development and commercialization efforts[195]. Agreements and Partnerships - The company entered into a Distribution Agreement with NXC Imaging, appointing NXC as the exclusive reseller of QT Breast Scanners in the U.S. and U.S. territories[137]. - The company has entered into a Manufacturing Agreement with Canon Medical Systems, appointing them as the exclusive manufacturer of QT Breast Scanners[138]. - The Amended Distribution Agreement with NXC could generate cash inflows of up to $18 million in 2025 and $27 million in 2026[170]. - The company plans to build a U.S. sales and marketing team and has appointed NXC as the exclusive agent for the QT Breast Scanner in the U.S.[189]. Loans and Financial Obligations - The company has a senior secured term loan of $10,100,000 with an interest rate of 10.0% per annum, maturing on March 31, 2027[144]. - The Lynrock Lake Term Loan provided $10.1 million in principal, with $5.4 million net proceeds available for working capital after settling obligations[171]. - The Lynrock Lake Term Loan has an aggregate principal amount of $10,100,000 with an interest rate of 10.0% per annum, maturing on March 31, 2027[173]. - As of March 31, 2025, the outstanding amount of the Lynrock Lake Term Loan was $697, net of the unamortized debt discount of $10,099,303[179]. - The company recorded a loss of $6,640,384 upon issuance of the Lynrock Lake Term Loan, including debt issuance costs of $244,300[179]. - As of March 31, 2025, the outstanding amount of the 2020 Notes was $3,143,725 with accrued interest of $592,887[181]. Operational Insights - The company has delivered fourteen QT Breast Scanners to NXC and its customers as of March 31, 2025[137]. - The company expects to remain cash flow negative for the foreseeable future, although it may achieve positive cash flows in certain quarters[169]. - Net cash used in operating activities for the three months ended March 31, 2025 was $3,536,799, a decrease from $5,975,515 for the same period in 2024[185]. - Net cash provided by financing activities for the three months ended March 31, 2025 was $5,352,198, primarily due to $10,000,000 of net proceeds from the Lynrock Lake Term Loan[187]. Legal and Compliance - The company is subject to occasional lawsuits and claims, but management is not aware of any pending claims that will materially impact financial statements[199]. - The company leases its operating facilities in Novato, California, under a non-cancelable operating lease through May 31, 2027[198]. - The company is classified as an emerging growth company (EGC) under the JOBS Act, allowing it to delay adopting new accounting standards[200]. - The company will remain an EGC until it meets certain revenue or filing criteria, including total annual gross revenue of at least $1.235 billion[203]. - The company has no off-balance sheet arrangements during the periods presented[197]. Strategic Goals - The company plans to create disruptive technological innovations to improve medical imaging quality and access[139]. - The company aims to expand its market by supporting Direct-to-Customer and Direct-to-Patient approaches to lower healthcare costs[139]. - The company has modified the conversion price for its promissory note with Yorkville to $0.584 per share[142]. - The Lynrock Lake Warrant allows for the purchase of 61,000,000 shares at an exercise price of $0.40 per share, exercisable until February 26, 2035[178]. - The company may need to relinquish valuable rights to technologies or revenue streams if it raises funds through collaborations or licensing arrangements[194]. - The company is unable to estimate exact operating capital requirements due to numerous risks and uncertainties associated with manufacturing and commercialization of products[191].

Financial Performance - Commercial revenue for Q1 2025 was $2.8 million, a 100% increase from $1.4 million in Q1 2024, driven by the shipment of six Breast Acoustic CT scanners[5] - Gross margin improved to 65% in Q1 2025, up from 56% in Q1 2024 and 47% in Q4 2024, attributed to variability in inventory costs[5] - Net loss for Q1 2025 was $11.1 million, compared to a net loss of $0.6 million in Q1 2024 and $3.5 million in Q4 2024[5] - Net loss for the three months ended March 31, 2025, was $11,136 thousand, compared to a net loss of $629 thousand in the same period of 2024[20] - Adjusted EBITDA is used as a non-GAAP measure to provide insights into financial performance, but specific figures for this measure were not disclosed in the report[25] Cash Flow and Financing - Net cash used in operating activities was $3.5 million in Q1 2025, down from $6.0 million in Q1 2024[6] - Net cash used in operating activities decreased to $3,537 thousand in Q1 2025 from $5,976 thousand in Q1 2024, indicating improved cash flow management[20] - Cash and restricted cash and cash equivalents at the end of the period were $3,008 thousand, down from $5,640 thousand at the end of Q1 2024[20] - Proceeds from long-term debt in Q1 2025 were $10,000 thousand, compared to $10,525 thousand in Q1 2024, reflecting ongoing financing efforts[20] - The company closed a $10.1 million term loan with Lynrock Lake, with $5.4 million allocated for working capital[2][9] - The company received $0.7 million in PIPE investment from board members and other investors for working capital[1][9] Growth and Future Projections - The company aims to achieve $18 million in revenue for 2025 and $27 million for 2026, corresponding to the shipment of 40 and 60 scanners respectively[10] - The company anticipates future growth in product sales and revenues related to the QT Imaging Breast Acoustic CT™ Scanner, although specific projections were not provided[21] Operational Developments - The company entered into a contract manufacturing agreement with Canon Medical Systems Corporation to enhance production capabilities[2][9] - The company is focused on expanding its product offerings and improving operational efficiency to enhance market competitiveness[21] - QT Imaging is committed to addressing identified material weaknesses in internal controls over financial reporting to improve overall governance[21] Market Position and Risks - Management highlighted risks related to the commercialization of new products and the ability to attract qualified personnel, which could impact future performance[21] - The company successfully uplisted to the OTCQB Venture Market on March 11, 2025, after being suspended from Nasdaq trading[9] - The company emphasizes the importance of medical imaging technology in improving global health outcomes and patient experience[30]

Financial Performance and Profitability - The company has incurred significant operating losses in the past and may never achieve or maintain profitability[28] - The company has a limited operating history with its current offerings, making it difficult to evaluate future business prospects[28] - The company has incurred significant operating losses in the past and may never achieve or maintain profitability[28] - The company has a limited operating history with its current offerings, increasing the risk of investment[28] - The company does not anticipate paying dividends on common stock, affecting potential returns for investors[33] Product Development and Market Acceptance - The company is dependent on the successful commercial launch of the QT Scanner 2000 Model A, which must achieve widespread market acceptance to generate necessary revenue[28] - The successful commercial launch of the QT Breast Scanner is critical for generating necessary revenue[28] - The company may not successfully develop or introduce new products that achieve market acceptance, which could harm revenue[28] Competition and Market Risks - The company faces risks related to increased competition and the ability to manage growth profitably following the Business Combination[21] - The company faces risks related to increased competition and the ability to manage growth effectively[28] Capital and Financing Needs - The company may need to incur additional indebtedness or seek capital through new equity or debt financings to support business growth[28] - The company may need to incur additional indebtedness or seek capital through new equity or debt financings to support growth[28] - The company's common stock is now quoted on the OTC Markets OTCQB Venture Market tier, which may adversely affect its ability to raise additional financing[33] - The common stock is now quoted on the OTC Markets OTCQB Venture Market tier, which may depress stock price and affect capital raising efforts[33] Management and Operational Challenges - The management team has limited experience managing a publicly traded company, which could affect the company's transition and operations[33] - The management team has limited experience managing a publicly traded company, which could affect business operations[33] Regulatory and External Factors - Recent changes in the United States related to payment policies for imaging procedures could negatively impact the utilization of the company's imaging services[28] - Recent changes in U.S. payment policies for imaging procedures could negatively impact the utilization of the company's services[28] Technology and Infrastructure - The company relies on a combination of patents and trade secrets to protect its proprietary technologies, and failure to maintain these protections could adversely impact market competitiveness[33] - The company relies on third-party providers for internet infrastructure and any failure could adversely affect customer relationships[28]

Exhibit 99.1 QT Imaging Announces Fourth Quarter and Full Year 2024 Financial Results and Provides 2025/26 Outlook Generated Sales of Twelve Scanners with Revenue of Approx. $5 Million and with 54% Gross Margin in 2024 Announced Insiders PIPE investment of $2.56 Million, fully funded by the QTI Board of Directors members and Management Announced the Closing of $10.1 million Lynrock Lake Term Loan, of which $5.4 million is for Working Capital Purposes Announced Clearing of All Its Short-Term Debt Liabilities ...

Financial Performance - The company has incurred a net loss of $9,166,958 during the nine months ended September 30, 2024, with an accumulated deficit of $32,122,605[179]. - Revenue increased by $931,313 to $955,970 for the three months ended September 30, 2024, compared to $24,657 for the same period in 2023, primarily due to the sale of two QT Breast Scanners[195]. - Cost of revenue increased by $326,868 to $350,667 for the three months ended September 30, 2024, from $23,799 for the same period in 2023, attributed to the sale of two QT Breast Scanners[196]. - Net loss for the three months ended September 30, 2024, was $3,619,494, compared to a net loss of $1,375,939 for the same period in 2023, reflecting an increase of $2,243,555[198]. - Revenue increased to $4,032,168 for the nine months ended September 30, 2024, up from $35,404 in the same period of 2023, representing a change of $3,996,764[206]. - Cost of revenue rose to $1,792,234 for the nine months ended September 30, 2024, compared to $73,497 in 2023, an increase of $1,718,737[207]. - Gross profit improved to $2,239,934 for the nine months ended September 30, 2024, from a loss of $(38,093) in 2023, a change of $2,278,027[206]. - Net loss for the nine months ended September 30, 2024, was $(9,166,958), an increase of $(4,578,058) from a net loss of $(4,588,900) in 2023[206]. - Interest expense increased to $3,149,315 for the nine months ended September 30, 2024, up from $394,714 in 2023, a change of $2,754,601[213]. Research and Development - The company expects to continue investing in research and development, particularly for the QT Breast Scanner and a full-body scanner product candidate, which may lead to increased costs[190]. - Research and development expenses rose by $613,385 to $925,214 for the three months ended September 30, 2024, from $311,829 for the same period in 2023, mainly due to increased employee compensation and professional services costs[197]. - Research and development expenses increased by 130% to $2,492,842 for the nine months ended September 30, 2024, from $1,083,373 in 2023[208]. Financing and Capital - The company issued a Yorkville Note for a Pre-Paid Advance of $10 million, with a payment of $1,521,581 made to Yorkville on September 13, 2024[181]. - The Company entered into a PIPE agreement for the issuance of shares and warrants with an aggregate purchase price of $2,560,000, resulting in the issuance of 4,383,558 shares at $0.584 per share[185]. - The company plans to raise additional capital through equity issuance, borrowings, and potential strategic alliances to support commercialization efforts[242]. - The company expects to fund its current operating plan for at least the next 12 months through additional cash received from financing arrangements and revenues[217]. - Net cash provided by financing activities for the nine months ended September 30, 2024 was $10,220,475, primarily from $10,525,000 of net proceeds from long-term debt issuance and $1,238,530 from the Merger[239]. Operational Agreements - The company entered into a Distribution Agreement with NXC Imaging, appointing them as the exclusive reseller of QT Breast Scanners in the U.S. and U.S. territories[174]. - The company has entered into a Feasibility Study Agreement with Canon Medical Systems to evaluate the QT Breast Scanner's business and clinical values[177]. - The company plans to engage in a binding Original Equipment Manufacturer (OEM) agreement with Canon Medical Systems, targeting execution in Q4 2024[178]. Expenses and Liabilities - The company expects to incur additional recurring administrative expenses associated with being a publicly traded company, including compliance costs and audit fees[180]. - Selling, general and administrative expenses increased by $1,075,153 to $2,007,277 for the three months ended September 30, 2024, from $932,124 for the same period in 2023, driven by higher employee compensation and insurance costs[199]. - Selling, general and administrative expenses surged by 221% to $9,873,029 for the nine months ended September 30, 2024, compared to $3,072,720 in 2023[209]. - The company has outstanding Related Party Convertible Notes Payable amounting to $3,143,725 as of September 30, 2024, with accrued interest of $507,029[231]. - The Cable Car Loan outstanding amount as of September 30, 2024 was $1,247,374, net of issuance costs of $252,626[230]. Cash Flow and Financial Position - As of September 30, 2024, cash and cash equivalents were $1,564,169, significantly up from $184,686 as of December 31, 2023[215]. - Net cash used in operating activities for the nine months ended September 30, 2024 was $8,806,402, compared to $1,965,772 for the same period in 2023, primarily due to funding research and development and general administrative expenses[236]. - The company has a cash flow increase of $1,379,483 for the nine months ended September 30, 2024, compared to a decrease of $420,586 for the same period in 2023[235]. Regulatory and Compliance - The company is an emerging growth company (EGC) and intends to rely on exemptions provided by the JOBS Act, delaying the adoption of new accounting standards until certain conditions are met[252]. - The company has total annual gross revenue of at least $1.235 billion, which will affect its status as an EGC[255]. - The company is currently evaluating the impact of new accounting standards issued in November and December 2023 on its financial statements[266][267]. Legal and Tax Matters - The company is subject to occasional lawsuits and claims, but management is not aware of any pending claims that will materially impact financial statements[251]. - The company evaluates the realizability of deferred tax assets annually, considering future taxable income and available tax planning strategies[263]. - The company adopted ASU 2020-06 effective January 1, 2024, with no material impact on its financial statements[265]. Revenue Recognition - The company recognizes revenue when a customer obtains control of promised goods or services, with specific steps outlined for revenue recognition[258].

Financial Performance - Scanner sales revenue for Q3 2024 was $0.9 million, with a gross margin of 65%[1] - Total commercial revenue for Q3 2024 was $1.0 million, down from $1.7 million in Q2 2024 and less than $0.1 million in Q3 2023[7] - Net loss for Q3 2024 was $3.6 million, compared to a net loss of $1.4 million in Q3 2023[7] - Non-GAAP Adjusted EBITDA for Q3 2024 was $(2.2) million, compared to $(0.6) million in Q3 2023[7] - Operating cash used in Q3 2024 was $1.9 million, compared to $0.4 million in Q3 2023[7] - Net loss for the nine months ended September 30, 2024, was $9,166,000, compared to a net loss of $4,589,000 for the same period in 2023, indicating a 99.5% increase in losses[19] Financing Activities - The company completed a $2.56 million PIPE financing, executed by Board members, at a 10% premium to the prior five-day average trading price[4] - The principal balance of the convertible note was reduced to $8.6 million after a payment of approximately $1.5 million[3] - Proceeds from long-term debt, net of issuance costs, amounted to $10,525,000 during the nine months ended September 30, 2024[19] Assets and Liabilities - Total current assets increased to $5,778,000 as of September 30, 2024, compared to $4,819,000 on December 31, 2023, representing a 19.9% increase[18] - Total liabilities rose to $16,612,000 as of September 30, 2024, up from $12,018,000 at the end of 2023, reflecting a 38.2% increase[18] - Cash and restricted cash and cash equivalents at the end of the period were $1,564,000, a significant increase from $54,000 at the end of the previous year[19] - The company reported a decrease in inventory to $3,182,000 as of September 30, 2024, down from $4,418,000, marking a 28.0% reduction[18] Strategic Initiatives - The company signed a third-year renewal of its five-year research grant from the NIH/NCI during Q3 2024[9] - The company plans to maintain revenue pace in Q4 2024 with expected higher gross margins due to inventory cost adjustments[11] - The company anticipates future growth in product sales and projected revenues related to the QT Imaging Breast Acoustic CT™ Scanner[20] - QT Imaging's strategy focuses on improving global health outcomes through innovative body imaging systems using low-frequency sound waves[31] Internal Controls - The company has identified material weaknesses in internal controls over financial reporting, which may impact future financial results[20] Definitions - Adjusted EBITDA is defined as EBITDA further adjusted for stock-based compensation and changes in fair value of liabilities, providing insight into the company's financial performance[25]

Group 1 - QT Imaging Holdings reported earnings per share of -30 cents for the second quarter of 2024 [1] - The company generated revenue of $1.71 million during the same period [1]

Financial Performance - The company has incurred a net loss of $5,547,464 and used $6,955,081 of cash in operating activities during the six months ended June 30, 2024, with an accumulated deficit of $28,503,111 as of the same date[147]. - Net loss for the three months ended June 30, 2024, was $1,248,874, a decrease of $81,140 compared to a net loss of $1,330,014 in the same period in 2023[179]. - Revenue increased by $1,710,852 to $1,714,035 for the three months ended June 30, 2024, compared to $3,183 for the same period in 2023, primarily due to the sale of four QT Breast Scanners[175]. - Revenue for the six months ended June 30, 2024, increased by $3,065,451 to $3,076,198 from $10,747 in 2023, primarily due to the sale of seven QT Breast Scanners[186]. - Cost of revenue increased by $836,363 to $839,484 for the three months ended June 30, 2024, from $3,121 in the same period in 2023, driven by the sale of four QT Breast Scanners[176]. - Cost of revenue for the six months ended June 30, 2024, increased by $1,391,869 to $1,441,567 from $49,698 in 2023, driven by the sale of seven QT Breast Scanners[189]. - Selling, general and administrative expenses increased by $1,320,710 to $2,169,541 for the three months ended June 30, 2024, from $848,831 in 2023, attributed to higher professional services and employee compensation costs[178]. - Selling, general and administrative expenses for the six months ended June 30, 2024, increased by $5,725,156 to $7,865,752 from $2,140,596 in 2023, largely due to non-recurring transaction expenses related to the business combination[191]. - Interest expense, net increased by $1,432,139 to $1,694,009 for the six months ended June 30, 2024, from $261,870 in 2023, primarily due to increased amortization of debt discount[194]. Financing Activities - The company raised a private secured convertible bridge financing of $1,000,000 on November 10, 2023, with four of the five investors opting for cash repayment totaling $960,000, while one investor converted $200,000 into 100,000 shares of common stock[151][152]. - On November 15, 2023, the company entered into a Standby Equity Purchase Agreement allowing the sale of up to $50 million of common stock over 36 months following the Business Combination[155]. - The company received a Pre-Paid Advance of $9,025,000 from Yorkville, accruing interest at 6%, with a potential increase to 18% upon default[155]. - The company raised $1,000,000 through a private secured convertible bridge financing, with $960,000 paid to four of the five Bridge Loan holders on the Merger Date[203]. - Net cash provided by financing activities was $11,398,512 for the six months ended June 30, 2024, primarily due to proceeds from the Yorkville Pre-Paid Advance and the Cable Car Loan[215]. - The company received a Pre-Paid Advance of $9,025,000 from Yorkville and $1,500,000 from Cable Car, with an additional $40 million available through the Standby Equity Purchase Agreement[197]. - The outstanding amount of the Cable Car Loan as of June 30, 2024, was $1,138,668, net of issuance costs[206]. - The company issued convertible notes with a total outstanding amount of $3,143,725 as of June 30, 2024, with accrued interest of $463,629[208]. Research and Development - The company expects research and development expenses to increase substantially as it invests in the QT Breast Scanner and a full-body scanner for orthopedic and pediatric use[170]. - The company expects to continue investing in product development, which may significantly affect future research and development costs[171]. - The company anticipates that its cost of revenue will increase in absolute dollars but decrease as a percentage of revenues over time due to new manufacturing processes[169]. - The company plans to engage in a good faith discussion to develop a binding Original Equipment Manufacturer (OEM) agreement with Canon Medical Systems, targeting execution in the second half of 2024[146]. - The company has entered into a Feasibility Study Agreement with Canon Medical Systems to evaluate the business, technical, and clinical values of the QT Breast Scanner, which will remain in force until the end of December 2024[145]. - The company aims to improve healthcare quality and access through disruptive innovation in medical imaging technology, including artificial intelligence and smart physics[142]. Operational Challenges - The company has been operating with negative cash flows since inception and will need to continue raising additional capital to achieve profitability[147]. - The company’s future capital requirements will depend on growth rate and spending for research and development, with potential challenges in raising additional financing[198]. - Future funding requirements will depend on factors such as cash availability for debt obligations, manufacturing expansion, and regulatory clearance costs[219]. - If financing is not available at acceptable levels, the company may need to reduce operating expenses or delay development programs[218]. - The company is subject to risks that could significantly increase operating capital requirements, including costs associated with product sales and regulatory reviews[219]. Internal Controls and Compliance - The company identified a material weakness in internal control over financial reporting due to lack of segregation of duties around key accounting processes, attributed to limited personnel resources[243]. - A second material weakness was identified related to technical accounting aspects of certain material transactions during the review of condensed consolidated financial statements for the three months ended March 31, 2024[243]. - Remedial measures have been initiated, including implementing technology, hiring personnel, and engaging external resources to address the identified weaknesses[243]. - No misstatements were found in the condensed consolidated financial statements as of June 30, 2024, despite the identified material weaknesses[244]. - There were no changes in internal control over financial reporting that materially affected the company's internal controls during the three months ended June 30, 2024[245]. - The effectiveness of internal control systems is subject to inherent limitations, including the exercise of judgment and resource constraints[246]. - The company plans to continue monitoring and upgrading internal controls as necessary but cannot assure that improvements will be sufficient for effective internal control over financial reporting[246]. Legal and Regulatory Matters - The company is not currently subject to any material legal proceedings, nor are any threatened against it or its officers[248]. - The company is classified as an emerging growth company, allowing it to delay adopting new accounting standards until certain conditions are met[225]. - Recent accounting standards updates adopted by the company had no material impact on its financial statements[237]. - The company is evaluating the impact of new accounting standards on its financial disclosures, effective for fiscal years beginning after December 15, 2023[238][239]. - The company is a smaller reporting company and is not required to provide certain market risk disclosures[240]. Manufacturing and Distribution - The company has focused on small-scale manufacturing internally while partnering for large-scale manufacturing to support market expansion[142]. - The company entered into a Distribution Agreement with NXC Imaging, appointing NXC as the exclusive reseller of QT Breast Scanners in the U.S. and U.S. territories, with four QT Breast Scanners delivered to NXC's customers as of June 30, 2024[142][144]. - The company entered into a Distribution Agreement with NXC, appointing them as the exclusive reseller for certain equipment in the U.S. until December 31, 2025[167]. - The company leases its operating facilities in Novato, California, under a non-cancelable lease through May 31, 2027[223].